Literature DB >> 1549969

Stenting of venous bypass grafts: a new treatment modality for patients who are poor candidates for reintervention.

I K de Scheerder1, B H Strauss, P J de Feyter, K J Beatt, L H Baur, W Wijns, G R Heyndrix, H Suryapranata, M van den Brand, B Buis.   

Abstract

During a 2-year period, 136 self-expanding Wallstents were implanted in saphenous vein bypass grafts in 69 patients with end-stage coronary artery disease. All patients had severe symptoms and the majority were poor candidates for either repeat surgery or conventional bypass coronary angioplasty because of unfavorable native anatomy, impaired left ventricular function, or a high-risk bypass lesion anatomy for coronary angioplasty. All procedures were technically successful without major complications and a need for emergency bypass surgery. However, during the hospital stay acute thrombotic complications occurred in seven patients (10%) resulting in one death and acute myocardial infarction in five patients and necessitating emergency repeat PTCA in two patients and repeat CABG in four. Twenty-three patients had serious hemorrhagic complications directly related to the rigorous anticoagulation schedule. Two patients died of fatal cerebral bleeding. During follow-up, another five patients died accounting for a total mortality rate of 12%. At late angiographic follow-up (4.9 +/- 3.4 months, n = 53), 25 patients (47%) had a restenosis (greater than or equal to 50% DS) within or immediately adjacent to the stent, necessitating reintervention in 19 patients (PTCA, n = 12; repeat CABG, n = 7). In the group without stent-related restenosis (n = 28), 15 patients had progression of disease in either the native or bypass vessels leading to recurrence of major anginal symptoms within 1 to 24 months. Ten of these patients required further intervention (stent, n = 6; PTCA, n = 3; repeat CABG, n = 1). Stenting in saphenous coronary bypass grafts can be performed safely with excellent immediate angiographic and clinical results.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1549969     DOI: 10.1016/0002-8703(92)90716-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Electrochemical polishing of 316L stainless steel slotted tube coronary stents.

Authors:  Hui Zhao; Jan Van Humbeeck; Jürgen Sohier; Ivan De Scheerder
Journal:  J Mater Sci Mater Med       Date:  2002-10       Impact factor: 3.896

2.  Comparison of self-expanding polyethylene terephthalate and metallic stents implanted in porcine iliac arteries.

Authors:  K Wilczek; I D Scheerder; K Wang; E Verbeken; J Piessens
Journal:  Cardiovasc Intervent Radiol       Date:  1996 May-Jun       Impact factor: 2.740

3.  Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries.

Authors:  I K De Scheerder; K L Wilczek; E V Verbeken; J Vandorpe; P N Lan; E Schacht; J Piessens; H De Geest
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Jul-Aug       Impact factor: 2.740

4.  Risk factors for the development of restenosis following stent implantation of venous bypass grafts.

Authors:  U E Heidland; M P Heintzen; C J Michel; B E Strauer
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

Review 5.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

6.  Evaluation of fluorinated polymers as coronary stent coating.

Authors:  I Verweire; E Schacht; B P Qiang; K Wang; I De Scheerder
Journal:  J Mater Sci Mater Med       Date:  2000-04       Impact factor: 3.896

7.  Clinical and angiographic acute and follow up results of intracoronary beta brachytherapy in saphenous vein bypass grafts: a subgroup analysis of the multicentre European registry of intraluminal coronary beta brachytherapy (RENO).

Authors:  T M Schiele; E Regar; S Silber; E Eeckhout; D Baumgart; W Wijns; A Colombo; W Rutsch; D Meerkin; A Gershlick; R Bonan; P Urban
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.